Your browser doesn't support javascript.
loading
PET Imaging for Initial Staging and Therapy Assessment in Multiple Myeloma Patients.
Bailly, Clément; Leforestier, Rodolphe; Jamet, Bastien; Carlier, Thomas; Bourgeois, Mickael; Guérard, François; Touzeau, Cyrille; Moreau, Philippe; Chérel, Michel; Kraeber-Bodéré, Françoise; Bodet-Milin, Caroline.
  • Bailly C; Nantes-Angers Cancer Research Center (CRCNA), University of Nantes, Inserm UMR 1232, 8 quai Moncousu, 44007 Nantes, France. clement.bailly@chu-nantes.fr.
  • Leforestier R; Department of Nuclear Medicine, CHU de Nantes, 1 place Alexis Ricordeau, 44093 Nantes, France. clement.bailly@chu-nantes.fr.
  • Jamet B; Department of Nuclear Medicine, CHU de Nantes, 1 place Alexis Ricordeau, 44093 Nantes, France. rodolpheleforestier@hotmail.fr.
  • Carlier T; Department of Nuclear Medicine, CHU de Nantes, 1 place Alexis Ricordeau, 44093 Nantes, France. bastien.jamet@chu-nantes.fr.
  • Bourgeois M; Nantes-Angers Cancer Research Center (CRCNA), University of Nantes, Inserm UMR 1232, 8 quai Moncousu, 44007 Nantes, France. thomas.carlier@chu-nantes.fr.
  • Guérard F; Department of Nuclear Medicine, CHU de Nantes, 1 place Alexis Ricordeau, 44093 Nantes, France. thomas.carlier@chu-nantes.fr.
  • Touzeau C; Nantes-Angers Cancer Research Center (CRCNA), University of Nantes, Inserm UMR 1232, 8 quai Moncousu, 44007 Nantes, France. mickael.bourgeois@nantes.inserm.fr.
  • Moreau P; Department of Nuclear Medicine, CHU de Nantes, 1 place Alexis Ricordeau, 44093 Nantes, France. mickael.bourgeois@nantes.inserm.fr.
  • Chérel M; Nantes-Angers Cancer Research Center (CRCNA), University of Nantes, Inserm UMR 1232, 8 quai Moncousu, 44007 Nantes, France. francois.guerard@univ-nantes.fr.
  • Kraeber-Bodéré F; Department of Nuclear Medicine, CHU de Nantes, 1 place Alexis Ricordeau, 44093 Nantes, France. cyrille.touzeau@chu-nantes.fr.
  • Bodet-Milin C; Department of Nuclear Medicine, CHU de Nantes, 1 place Alexis Ricordeau, 44093 Nantes, France. philippe.moreau@chu-nantes.fr.
Int J Mol Sci ; 18(2)2017 Feb 18.
Article en En | MEDLINE | ID: mdl-28218709
ABSTRACT
Multiple myeloma (MM) is a hematological neoplasm characterized by the clonal proliferation of malignant plasma cells in the bone marrow. MM results in diffuse or focal bone infiltration and extramedullary lesions. Over the past two decades, advances have been made with regard to the diagnosis, staging, treatment, and imaging of MM. Computed tomography (CT) and magnetic resonance imaging (MRI) are currently recommended as the most effective imaging modalities at diagnostic. Yet, recent data from the literature suggest that positron emission tomography combined with computed tomography (PET/CT) using 18F-deoxyglucose (FDG) is a promising technique for initial staging and therapeutic monitoring in this pathology. This paper reviews the recent advances as well as the potential place of a more specific radiopharmaceutical in MM.
Asunto(s)
Palabras clave

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Tomografía de Emisión de Positrones / Mieloma Múltiple Tipo de estudio: Diagnostic_studies / Etiology_studies / Prognostic_studies Límite: Humans Idioma: En Año: 2017 Tipo del documento: Article

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Tomografía de Emisión de Positrones / Mieloma Múltiple Tipo de estudio: Diagnostic_studies / Etiology_studies / Prognostic_studies Límite: Humans Idioma: En Año: 2017 Tipo del documento: Article